Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Sensorion

Market Cap 128M 149M 118M 111M 209M 14.05B 211M 1.4B 545M 6.89B 559M 547M 23.85B P/E 2026 *
-16.6x
P/E 2027 * -3.84x
Enterprise Value -3.58M -4.15M -3.29M -3.1M -5.82M -391M -5.87M -38.98M -15.17M -192M -15.56M -15.23M -664M EV / Sales 2026 *
-0.16x
EV / Sales 2027 * 20.1x
Free-Float
70.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 01/06/2026
Director of Finance/CFO - 26/06/2024
Chief Tech/Sci/R&D Officer - 11/12/2023
Director TitleAgeSince
Director/Board Member - 09/03/2015
Director/Board Member 43 -
Chairman 61 30/03/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 149M
-0.22%-1.14%-11.88%-10.15% 43.51B
+2.07%+11.53%+310.88%+526.25% 33.29B
-0.43%+0.19%+3.94%+37.87% 29.34B
-3.60%-6.13%+10.97%-20.43% 29.9B
+0.06%+2.71%+13.31%+21.11% 25.42B
+0.61%+10.73% - - 14.36B
+0.22%-0.83%+55.03%+105.02% 13.18B
-0.29%-4.40%+3.13%+4.23% 12.72B
+1.28%+1.31%+105.48%+80.86% 12.08B
Average -0.08%+0.67%+61.36%+93.09% 23.76B
Weighted average by Cap. -0.26%+0.72%+63.44%+102.93%

Financials

2026 *2027 *
Net sales 21.86M 25.34M 20.1M 18.91M 35.54M 2.39B 35.84M 238M 92.72M 1.17B 95.09M 93.06M 4.06B 6.4M 7.41M 5.88M 5.53M 10.4M 700M 10.49M 69.68M 27.13M 343M 27.82M 27.23M 1.19B
Net income -4.34M -5.03M -3.99M -3.76M -7.06M -475M -7.12M -47.29M -18.41M -233M -18.88M -18.48M -806M -50.64M -58.7M -46.56M -43.82M -82.34M -5.54B -83.04M -552M -215M -2.72B -220M -216M -9.41B
Net Debt -132M -153M -121M -114M -215M -14.44B -216M -1.44B -560M -7.09B -574M -562M -24.52B -
Logo Sensorion
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. The company has two gene therapy programmes: SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, and SENS-601 (GJB2-GT) for the treatment of hearing loss associated with mutations in the GJB2 gene.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.2495EUR
Average target price
1.212EUR
Spread / Average Target
+385.97%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!